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Abstract
Objectives: Benign liver tumours (BLTs) are common and their management remains controversial. This
study assesses the safety of a selective management approach.
Methods: Patients with BLT were identified from an institutional database. Patients with simple cysts or
an incidental BLT in the setting of metastasis or concomitant malignancy were excluded.
Results: A total of 285 patients presenting during the period from January 1992 to December 2009 with
haemangioma (53.0%), focal nodular hyperplasia (23.9%), adenoma (10.2%) or indeterminate/other
lesions (13.0%) were evaluated. Of these, 117 patients (41.1%) underwent immediate resection and 168
patients (58.9%) were followed with serial imaging (median follow-up: 30 months). During observation,
eight patients (4.8%) underwent resection for tumour growth, inability to exclude malignancy or symp-
toms; no patients demonstrated malignant transformation or tumour-related complications. During the
study period, the number of BLTs evaluated and the proportion of patients observed increased from 129
BLTs of which 36.4% were observed in 1992–2002 to 156 BLTs of which 71.2% were observed in
2003–2009 (P < 0.001). Diagnostic uncertainty led to resection in 29.5% of patients during the earlier
period, but in only 13.4% during the more recent 7 years (P < 0.05).
Conclusions: Asymptomatic BLTs without concern for malignancy or adenoma can be safely observed
with minimal risk for misdiagnosis. Patients selected for observation rarely require resection or develop
tumour-related complications.
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Introduction
Because of the prevalent use of cross-sectional imaging, benign
liver tumours (BLTs) are diagnosed with increasing frequency.1
The exact prevalence of these lesions remains unknown;
however, autopsy series report incidences of BLTs of up to 50%
and describe the most common of these tumours as haeman-
gioma, focal nodular hyperplasia (FNH) and hepatic adenoma.2,3
In addition to these well-characterized BLTs, other incidental
imaging findings include simple and atypical cysts, focal fatty
sparing and hepatic cystadenoma. The challenge of managing
liver lesions that are found incidentally stems from the inability
to definitively exclude malignancy or adenoma, which is associ-
ated with a small but real risk for bleeding or malignant trans-
formation. In the past, surgical intervention was advocated for
such findings in view of their uncertain clinical behaviour.
However, with improvements in cross-sectional imaging and a
better understanding of the natural history of BLTs, surveillance
has become the preferred option in most patients.4,5 Even in
cases of small (<5 cm) adenomas, non-operative management
has been reported in carefully selected patients.6 Nevertheless,
longterm follow-up data from large series to support observa-
tion in these patients are lacking.
This study was presented in part at the 64th Annual Cancer Symposium of
the Society of Surgical Oncology, 2–5 March 2011, San Antonio, Texas.
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The advent of laparoscopic liver resection potentially indicates
a lower threshold for resection of BLTs.7 In large published series
of laparoscopic liver resections, as many as 15–20% of resections
per year are performed for benign diagnoses.8–12 This is by contrast
with large series of patients treated with open liver resection.13–15
Despite improvements in operative techniques, morbidity from
liver resection remains significant4,14 and potentially outweighs the
perceived benefit of resecting benign tumours when observation
carries minimal risk.
The objective of this study was to analyse the management
strategy in use at Memorial Sloan–Kettering Cancer Center
(MSKCC) for patients with BLTs in order to determine trends over
time and to establish the natural history of BLTs in patients
selected for observation.
Materials and methods
Following institutional review board approval, patients diagnosed
and treated at MSKCC from January 1992 to December 2009 were
identified. Patients were identified from a prospective hepatopan-
creatobiliary operative database and an institutional ICD-9 search
(codes 211.5 and 235.3). The databases were queried for patients
with primary diagnoses of BLT, including patients with either
clinical or pathologic diagnoses of haemangioma, FNH, hepatic
adenoma or any other benign or indeterminate liver lesion.
Patients with simple hepatic cysts, hydatid cysts or incidental BLT
in the setting of active, concomitant malignancy were excluded
from analysis. To be included in the study, patients were required
to have undergone either resection or follow-up evaluation and
imaging at MSKCC. A portion of the patients treated between
1992 and 2000 have been reported in previous publications.4,16
Medical records were reviewed for clinicopathologic variables
known at the time of diagnosis, including age, gender, indication
for initial imaging, symptoms at presentation, initial imaging
modality, subsequent imaging modality, history of cancer and
prior cancer diagnosis, and tumour size and location. In patients
treated with hepatic resection, the timing of surgery (i.e. imme-
diately after initial presentation or after a period of observation)
was recorded. In addition, indications for surgery, type of
liver resection and final pathology were determined. In patients
who underwent observation, data on clinical diagnosis, intervals
between imaging studies, changes in tumour size and adjunctive
procedures performed were collected. Adjunctive procedures
obtained from medical records included percutaneous biopsy,
diagnostic laparoscopy, radiofrequency ablation (RFA) and
hepatic arterial embolization.
Radiologic assessment
The major imaging modalities used in the diagnosis of BLT
included ultrasonography (US), computed tomography (CT) and
magnetic resonance imaging (MRI). Benign liver tumours were
diagnosed on contrast-enhanced, multi-phase CT and/or MRI
when characteristic imaging features were identified. Routine
MRI of the liver was performed using 1.5 T magnetic resonance
scanners (GE Medical Systems, Milwaukee, WI, USA). Images
included pre-contrast T1 weighted (T1w) in-phase and out-of-
phase gradient echo, fat-suppressed T2 weighted (T2w) fast-
spin echo (FSE), T2w single-shot FSE and high-resolution
fat-suppressed three-dimensional T1w gradient echo sequences.
These were obtained prior to and following i.v. administration
of 0.1 mmol/kg of body weight gadopentetate dimeglumine
(Magnevist®; Berlex Laboratories, Inc., Wayne, NJ, USA) during
the arterial, portal venous and equilibrium phases. The general
imaging findings used to diagnose haemangioma, FNH and
adenoma are shown in Table 1.
Management algorithm
This group has previously published an algorithm for patients
with incidental liver tumours, which continued to evolve over the
time period covered in this retrospective review.4 The algorithm
served as a general guide throughout the period covered by this
study because patients with BLTs demonstrate clinical variability.
This institution’s current management algorithm is illustrated
in Fig. 1. Patients are discussed at weekly hepatopancreato-
biliary multidisciplinary conferences that include surgeons,
Table 1 Classic imaging characteristics of benign liver tumoursa
Lesion CT pre-contrast MRI T1 and T2 weighted
images
CT or MRI post-contrast Other
Haemangioma Hypoattenuating T1 hypointense and T2
hyperintense
Discontinuous peripheral
nodular enhancement
with centripetal fill-in
Enhancing components
as bright as adjacent
vascular pool
Focal nodular
hyperplasia
Isoattenuating T1 and T2 isointense with
T2 hyperintense central
scar
Avid homogeneous arterial
enhancement
If present, delayed
enhancement of
central scar
Adenoma Isoattenuating or
hypoattenuating
if fat present
T1 and T2 isointense, with
possible fat on in- and
out-of-phase imaging
Moderate homogeneous or
heterogeneous arterial
enhancement
May present with
haemorrhage
aOn MRI, isotensity, hypointensity and hyperintensity are relative to a normal liver parenchyma. A background of fatty liver may alter the relative T1
and T2 signals of benign liver lesions.
CT, computed tomography; MRI, magnetic resonance imaging.
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gastroenterologists and radiologists who specialize in liver
imaging. The imagingmodality of choice in this institution for the
evaluation of incidental or indeterminate liver lesions is MRI.17,18
This practice is in accordance with the American College of
Radiology Appropriateness Criteria for the characterization of
liver lesions.19
In general, patients with obvious malignancy, hepatic adenoma
of >5 cm, cystadenoma or lesions in which malignancy could
not be excluded were advised to undergo resection. Patients with
clearly symptomatic lesions, regardless of aetiology, were treated
with resection. Patients with hepatic adenomas of >5 cm in size
were treated with immediate resection because of the risk for
hepatocellular carcinoma or haemorrhage. Selected patients with
small adenomas (<5 cm) underwent serial imaging with discon-
tinuation of oral contraceptive medications (if appropriate); in
certain patients, hepatic artery embolization was employed. The
operative approach depended on the size and location of the
tumour. Large and/or deeply situated tumours, as well as those of
uncertain aetiology, were generally removed by formal resection,
whereas more superficial tumours, even if large, were usually
approached with enucleation.
Asymptomatic patients with lesions that met imaging criteria
for a benign lesion entered surveillance. In general, initial repeat
imaging was performed at 3 months and 6 months after the initial
visit. When the lesion had remained stable for 6 months, repeat
imaging was performed at 6-month intervals for 1 year and annu-
ally thereafter. The decision to continue surveillance after 1 year
was made by the attending surgeon and was highly variable
depending on the diagnosis. Themost commonly utilized imaging
modality for surveillance was MRI.
Patients with lesions that could not be fully characterized on
imaging, but were considered to represent low risk for malig-
nancy, were monitored closely with serial imaging in which the
first repeat imaging was performed at 3 months. In selected
patients with liver lesions similar to, but not diagnostic of, FNH,
haemangioma or cyst (atypical), short follow-up imaging was
performed. Patients in whom imaging documented stability for
>1 year, with no significant risk factors for malignancy, underwent
continued observation.
Patient follow-up
Dates of last follow-up were determined for all patients. Median
follow-up was calculated from the date of original BLT diagnosis
to last follow-up. Charts were reviewed to determine whether or
not patients initially selected for observation had eventually
required resection. Patients selected for observation were typically
followed at 6-month intervals with repeat imaging. All imaging
of patients maintained under observation was retrospectively
reviewed to determine changes in liver lesion size over time.
Statistical analysis
Clinical and pathologic factors in patients treated with immediate
surgery were compared with those in patients selected for obser-
vation using Student’s t-test. Numbers of tumours treated and
observed over time were compared using the Cochrane–Armitage
trend test in sas Version 9.2 (SAS Institute, Inc., Cary, NC,
USA).20 A P-value of <0.05 was considered to indicate statistical
significance.
Results
During the 18-year study period, 526 patients were diagnosed
with a BLT; 285 of these patients met the study criteria for analysis.
Clinical and treatment-related variables in the cohort are shown
Hepatic tumour with solid component
(CT or ultrasound)
Contrast-enhanced MRI
Atypical lesion with low
suspicion for malignancy
Unable to characterize or
suspicious for malignancy
Adenoma
Classic FNH
or haemangioma
Observation
Stability Increase size Resect
Resect
Biopsy
Non-operative therapyb
Observeb
Observea
Resect Observea
Resectable Unresectable Multifocal < 5 cm > 5 cm Symptomatic Asymptomatic
Figure 1 Current management algorithm for patients with benign liver tumours at Memorial Sloan–Kettering Cancer Center. This algorithm
serves as a general guide and is not based on level I evidence. aRepeat MRI in 3 months; bMedical or other interventional treatment;
CT, computed tomography; MRI, magnetic resonance imaging; FNH, focal nodular hyperplasia
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in Table 2. Abdominal pain was the most common indication
for imaging (35.8%) and CT scan (57.5%) was the most common
initial imaging modality. Of the 285 patients evaluated, 125
(43.9%) underwent hepatic resection and the remaining 160
(56.1%) patients were observed. There were no perioperative
deaths within 90 days of resection. Figure 2 illustrates treatment-
related outcomes in the 285 patients with BLT.
During the period covered by this study, 3704 liver resections
(including enucleations) were performed at MSKCC; 125 (3.4%)
were performed for a diagnosis of BLT. Characteristics of resected
patients are shown in Table 3. A total of 117 patients (41.1%) in
this study cohort underwent immediate resection. The reasons for
initial resection were a diagnosis of adenoma or the inability to
exclude malignancy (n = 80, 68.4%) and presence of symptoms
(n = 37, 31.6%). During the period of follow-up for resected
patients (median: 16 months; range: 1–183 months), no patient
developed recurrent or new liver lesions.
A total of 168 patients (58.9%) were initially selected for obser-
vation. The median follow-up of observed patients was 30 months
(range: 1–205 months). During this observation period, eight
patients (4.8%) eventually required resection for symptoms or
increasing tumour size and inability to rule out malignancy.
Clinicopathologic variables in resected and observed patients are
shown in Table 3. Patients treated with resection were younger,
had larger tumours, and more often had tumours located in the
left hepatic lobe compared with observed patients.
Specific histopathologies
Haemangioma
A total of 151 patients (53.0%) were diagnosed with haemangi-
oma during the evaluation period. Among these patients, 60
(39.7%) went directly to resection and 28 of these (46.7%) were
treated for symptoms caused by the tumour; lesions in the
remaining 32 patients (53.3%) could not be definitively diagnosed
on imaging. Notably, only four (12.5%) of the patients in whom
diagnostic uncertainty related to haemangiomata on imaging
were seen in the last 10 years of the study period. No patients in
this series had a preoperative diagnosis of haemangioma that was
contradicted on final pathology. Of the patients with haemangi-
oma, 91 (60.3%) were selected for observation and four (4.4%) of
these eventually underwent resection for the management of
tumour-related symptoms or a significant increase in tumour
size. One patient initially observed for an atypical haemangioma
subsequently underwent a resection that confirmed the diagnosis.
Table 2 Clinical and treatment-related variables in 285 patients with
benign liver tumours
Clinical variable Value
Age, years, median (range) 50 (12–84)
Female, n (%) 208 (73.0%)
Indication for initial image, n (%)
Abnormal liver function tests 22 (7.7%)
Cancer surveillance 68 (23.9%)
Extra-abdominal evaluation 93 (32.6%)
Abdominal pain 102 (35.8%)
Initial imaging modality, n (%)
Ultrasonography 92 (32.3%)
Computed tomography 164 (57.5%)
Magnetic resonance imaging 27 (9.5%)
Nuclear medicine study 2 (0.7%)
Subsequent imaging modality, n (%)
Magnetic resonance imaging 96 (33.7%)
Computed tomography 31 (10.9%)
Ultrasonography 18 (6.3%)
History of cancer, n (%) 109 (38.2%)
Prior cancer diagnosis, n (%)
Breast 27 (9.5%)
Genitourinary 26 (9.1%)
Colorectal 14 (4.9%)
Sarcoma 11 (3.9%)
Endocrine 10 (3.5%)
Melanoma 5 (1.8%)
Leukaemia/lymphoma 4 (1.4%)
Lung 4 (1.4%)
Upper gastrointestinal 4 (1.4%)
Other 4 (1.4%)
Tumour size, cm, median (range) 3.6 (0.3–35)
Tumour location, n (%)
Right lobe 184 (64.6%)
Left lobe 96 (33.7%)
Caudate lobe 3 (1.1%)
Bilateral 2 (0.7%)
Percutaneous biopsy, n (%) 56 (19.6%)
Resection, n (%) 125 (43.9%)
Presentation with BLT
January 1992 to
December 2009
n = 285
Resection
(n = 117)
41.1%
Observation
(n = 168)
58.9%
Resection
(n = 8)
4.8%
Observation
(n = 160)
95.2%
Figure 2 Presentation and outcomes in 285 patients with benign
liver tumours (BLTs)
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Focal nodular hyperplasia
Among the 68 patients (23.9%) with FNH, 42 (61.8%) were
initially diagnosed definitively on imaging. Of these 42 patients,
nine (21.4%) underwent immediate resection for tumour-related
symptoms. Three patients had atypical FNH on imaging; two
underwent immediate resection and one underwent resection
after a period of observation had failed to definitively rule out
malignancy. Final pathology results in all of these patients were
consistent with FNH. The 23 remaining patients were diagnosed
with FNH after resection of a suspected adenoma or malignancy;
only 11 of these patients underwent resection in the last 10 years
of the study period.
Of the 42 patients in whom FNH was diagnosed on imaging,
33 (78.6%) were selected for observation, one (3.0%) of whom
eventually underwent resection because of the development of
tumour-related symptoms from a left lateral segment lesion.
Hepatic adenoma
Hepatic adenoma was the final diagnosis in 29 patients (10.2%),
16 of whom (55.2%) went directly for resection. Eight patients
(27.6%) were treated with hepatic artery embolization and two
patients eventually underwent resection for adenomas that grew
in size during an initial trial of medical management and obser-
vation. Three patients with adenomas were selected for observa-
tion; of these, two had very small adenomas that remained stable
over time and one had comorbidities that precluded major
hepatic resection.
Other histopathology or indeterminate lesions
Twelve patients (4.2%) demonstrated other lesions that were
treated with initial resection because imaging did not support a
definitive diagnosis. Final pathologic analysis in these patients
revealed angiomyolipoma (n = 3), atypical hepatic cyst (n = 2),
cystadenoma (n = 4), hamartoma (n = 1), inflammatory mass
(n = 1) and solitary fibrous tumour (n = 1). The observation
group included patients with fatty sparing (n = 4), atypical hepatic
cysts (n = 5) and cystadenoma (n = 1), the last of which occurred
in a patient with contraindications for resection. One patient
had an angiomyolipoma that was treated with hepatic artery
embolization.
Fourteen patients in the observation group (8.3%) had inde-
terminate lesions; eight of these underwent either percutaneous
or laparoscopic liver biopsy to exclude malignancy. All patients
underwent serial imaging every 6 months to ensure stability; the
median follow-up was 17 months (range: 6–93 months). None of
these lesions increased in size during surveillance.
Among the 168 patients selected for initial observation, eight
(4.8%) eventually went on to liver resection. The characteristics of
these patients are summarized in Table 4.
Adjunct procedures
Several of the patients in the observation group underwent sec-
ondary procedures to assist with diagnosis and treatment. Two
patients with haemangiomata and two patients with adenomas
underwent laparoscopy with biopsy. Eight patients with adenoma
Table 3 Clinicopathologic variables in resected and observed patients with benign liver tumours
Clinical variable Resected (n = 125) Observed (n = 160) P-valuea
Age, years, mean  SD 46  12.9 52  13.1 <0.0001
Tumour size, cm, median (range) 6.0 (0.3–35.0) 3.0 (0.7–17.0) <0.0001
Tumour location, n (%)
Right lobe 66 (52.8%) 118 (73.8%) 0.04
Left lobe 59 (47.2%) 37 (23.1%) 0.04
Caudate 0 3 (1.9%) NS
Bilateral 0 2 (1.3%) NS
Percutaneous biopsy, n (%) 26 (20.8%) 30 (18.8%) NS
Final pathologic diagnosis, n (%)
Adenoma 18 (14.4%) -
Focal nodular hyperplasia 34 (27.2%)
Haemangioma 61 (48.8%)
Cystadenoma 4 (3.2%)
Angiomyolipoma 3 (2.4%)
Atypical cyst 2 (1.6%)
Solitary fibrous tumour 1 (0.8%)
Inflammatory mass 1 (0.8%)
Hamartoma 1 (0.8%)
aTwo-sided t-test.
NS, not significant; SD, standard deviation.
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and one patient with angiomyolipoma underwent hepatic artery
embolization, and one patient with FNH underwent RFA. Percu-
taneous biopsy was performed in 56 patients (19.6%).
Trend in the management of BLT
The trend in the management of BLT at MSKCC is shown in
Fig. 3. There was a significant increase in the number of BLTs
diagnosed over time and a significant trend toward observation
rather than resection. Data for patients who underwent serial
imaging at intervals of 6 months (n = 130) were also analysed.
Themedian follow-up in this cohort was 30months (range: 1-205
months) following the initial 6-month interval image. The
median initial tumour size in this group was 2.7 cm (range: 0.7–
14.0 cm) and the median final tumour size was 2.6 cm (range:
0.5–17.3 cm); this difference was not significant. A graphical
representation of tumour size over time in observed patients is
shown in Fig. 4.
Discussion
The findings of the present study suggest that most patients
with a BLT can remain subject to observation with low risk for
misdiagnosis, complications or malignant transformation. In the
present series of 285 patients, 117 underwent immediate resection
for symptoms or suspicion of cancer. During the time covered by
the study, the percentage of patients who were taken for immedi-
ate resection significantly declined in more recent years. From
the beginning of 2004 to the end of 2009, 30 of the 136 patients
seen (22.1%) were submitted to resection. Furthermore, surgery
for BLT comprised <3% of hepatic resections performed annually.
This can be attributed to: (i) improvements in cross-sectional
imaging;21 (ii) a better understanding of the natural history of
BLTs, and (iii) a multidisciplinary approach to the management
of these tumours.
Laparoscopic liver surgery has gained in popularity in the last
10 years and, to date, several large laparoscopic case series have
been published.11 Recently, a consensus conference published a
statement regarding the use of laparoscopic liver surgery in the
treatment of BLTs. The statement indicated that the threshold for
removal of BLTs should not change despite the development of a
Table 4 Clinicopathologic variables in eight patients initially selected for observation who underwent hepatic resectiona
Age, years,
gender
Prior cancer
history
Initial clinical
diagnosis
Year
diagnosed
Size and location
of lesion
Observation
period, months
Final pathology
37, female None Atypical FNH 2003 2.5 cm, right lobe 10 FNH
38, male Colon cancer Indeterminate 2007 1.5 cm, left lobe 9 Angiomyolipoma
44, female None Haemangioma 2005 10.0 cm, left lobe 9 Haemangioma
48, female None Haemangioma 2008 15.0 cm, right lobe 46 Haemangioma
50, male None Haemangioma 2003 7.3 cm, right lobe 88 Haemangioma
51, female Lymphoma FNH 2007 4.0 cm, left lobe 13 FNH
51, female None Haemangioma 2000 3.5 cm, left lobe 11 Haemangioma
58, female None Atypical haemangioma 2004 3.0 cm, right lobe 11 Haemangioma
aAll patients underwent resection for increasing size, inability to definitely rule out malignancy or occurrence of significant symptoms.
FNH, focal nodular hyperplasia.
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minimally invasive technique for resection.22 However, several
published series of laparoscopic hepatectomy demonstrate a
different pattern whereby up to 60% of patients resected had a
benign diagnosis, even in more recent series.8–10,12 This contrasts
with large series of open hepatectomy, in which BLTs account
for a minority of the patients resected.13–15 In the present series,
during 2004–2009, 22.1% of patients underwent immediate
resection, which represents a significant change from the 87.0%
(1992–1997) and 48.0% (1998-2003) of patients who did so in
earlier periods. Despite this significant change, an immediate
resection rate of 22.1% may still be slightly higher than might be
expected for all patients presenting with BLT. This observation
may reflect the fact that these patients were being treated at a
tertiary care centre for malignant disease and therefore may not
represent findings in other general hospitals.
This institution’s current algorithm for the management of
BLTs is shown in Fig. 1. Asymptomatic patients with haemangi-
oma or FNH that can be definitively diagnosed with high-quality
cross-sectional imaging are selected for observation. Lesions that
appear benign yet do not fit criteria for haemangioma, FNH or
adenoma are subjected to close short-term follow-up imaging to
ensure stability. Patients taken for immediate resection include
those with symptomatic tumours or lesions in which malignancy
cannot be excluded. Patients with definitive hepatic adenoma
or cystadenoma are also treated with surgery in view of the risk
for complications, including malignant transformation. This
management algorithm for adenomas is based primarily on size
and operative fitness.6 Some patients with hepatic adenoma or
adenomatosis may be treated with hepatic artery embolization.23
Radiofrequency ablation is another modality that can be utilized
for small adenoma or FNH in selected patients, although its
applicability is generally limited in this setting. The present
authors wish to emphasize, however, that efforts should be made
to establish the diagnosis histologically before such ablative
treatments are rendered.
In the present series, in patients in whom repeat imaging
demonstrated stability for 6 months, the likelihood that sur-
gical intervention would be required was 4.8% (eight of 168
patients). Similar findings have been demonstrated by other
groups. Weimann et al.5 reported a series of 437 patients seen
between 1980 and 1993 with haemangioma, FNH, adenoma
and mixed tumours; 173 patients (39.6%) underwent resection.
At a median follow-up of 32 months, none of the 104 patients
with haemangioma or the 53 patients with FNH had developed
complications or malignancy; however, 12 of the 157 observed
patients (7.6%) eventually underwent hepatic resection for treat-
ment of significant symptoms.
In the present series, the optimal duration of follow-up in
patients in the observation group with benign lesions was not
determined from this analysis and remains unknown. Several
of the asymptomatic patients with definitive diagnoses of FNH or
haemangioma remained in observation for many years, although
this is almost certainly unnecessary, especially when a definitive
diagnosis can be made on imaging. In part, the reason for the
prolonged follow-up in many patients refers to the history of
cancer in 38.2% of the cohort; thus,many patients were submitted
to surveillance for cancer and therefore imaging of their BLT was
available for analysis. At present, if imaging in a patient fits defini-
tive criteria for haemangioma or FNH, follow-up imaging may be
appropriate at some point to ensure the stability of the findings;
however, prolonged follow-up with serial imaging is unnecessary.
Additionally, questions about the most appropriate methods of
managing definitively diagnosed FNH or haemangiomata that
show signs of growth over time arise frequently. Although this
recommendation is controversial, the present authors generally
advise against surgery in most such cases unless symptoms have
arisen.
This study has several limitations. Patients who presented with
indeterminate or atypical benign liver lesions and who underwent
resection and were found to have cancer would not have been
included in this review. The study is retrospective in nature and
therefore it is possible that some patients were missed and not
included in the database. Furthermore, the study institution is a
tertiary care cancer centre and thus holds a status that can lead to
referral bias and is also likely to account for the observation that
38.2% of the patients had a prior history of cancer, which is a
higher proportion than in other reports.5
Despite the findings herein, it is critical to maintain suspicion
for malignancy until proven otherwise. The data presented
suggest that a clear-cut diagnosis of BLT after triple-phase
contrast CT and/or contrast-enhanced MRI may be made in
many patients, and such lesions may be safely observed. Inde-
terminate lesions, such as atypical FNH or haemangioma,
should be subjected to close follow-up to ensure stability. Com-
parative imaging is paramount in patients who initially present
with an atypical or indeterminate lesion with benign features.
In view of the aggressive nature of primary hepatic tumours,
there is concern that a potentially treatable cancer may become
untreatable during observation. These lesions are encountered
with increasing frequency and improvements in cross-sectional
imaging enable a clinical diagnosis of a BLT to be made with
more certainty. Although the current study did not specifi-
cally evaluate this matter, the present authors propose that
the advent of minimally invasive hepatectomy should not
change the indications for hepatectomy in patients with BLTs.
Theoretically, as the incidence of BLTs increases, the percentage
of patients who require resection should decrease over time
with the widespread adoption of selective management of these
lesions.
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